keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic oncology group

keyword
https://www.readbyqxmd.com/read/29903391/use-of-a-web-based-app-to-improve-postoperative-outcomes-for-patients-receiving-gynecological-oncology-care-a-randomized-controlled-feasibility-trial
#1
Ilana Graetz, Janeane N Anderson, Caitlin N McKillop, Edward J Stepanski, Andrew J Paladino, Todd D Tillmanns
OBJECTIVE: Nearly 1 in 5 patients hospitalized for ovarian cancer surgery are readmitted for complications that may have been prevented with monitoring. We conducted a randomized controlled feasibility trial to evaluate a postoperative web-based app intervention to provide real-time symptom monitoring among patients diagnosed or with suspected gynecological cancer who had open bilateral salpingo-oophorectomy surgery. METHODS: Participants were randomized into two groups: (1) App + Reminder: had access to the app, and use was encouraged with daily and/or weekly reminders; (2) app: had access to the app but received no reminders...
June 11, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29884437/is-carboplatin-based-chemotherapy-as-effective-as-cisplatin-based-chemotherapy-in-the-treatment-of-advanced-stage-dysgerminoma-in-children-adolescents-and-young-adults
#2
Rachana Shah, Caihong Xia, Mark Krailo, James F Amatruda, Suren G Arul, Deborah F Billmire, William E Brady, Allan Covens, David M Gershenson, Juliet P Hale, Jean Hurteau, Matthew J Murray, James C Nicholson, Thomas A Olson, Farzana Pashankar, Carlos Rodriguez-Galindo, Furqan Shaikh, Daniel Stark, A Lindsay Frazier, Sara Stoneham
OBJECTIVE: Dysgerminoma is the most common malignant ovarian germ cell tumor (GCT) with peak incidence during adolescence and young adulthood. Current standard of care for patients with disease that has spread outside of the ovary (advanced-stage) utilizes platin-based chemotherapy regimens. The study objective was to compare clinical outcomes between platin-based (carboplatin versus cisplatin) strategies across all age groups (children < 11 years (y), adolescents = 11-25 y and young adult women > 25 y) for advanced-stage dysgerminoma...
June 5, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29882024/inverse-relationship-between-reduced-fatigue-and-severity-of-anemia-in-oncology-patients-treated-with-integrative-medicine-understanding-the-paradox
#3
Eran Ben-Arye, Ofer Dahan, Ilanit Shalom-Sharabi, Noah Samuels
OBJECTIVE: To assess the impact of integrative medicine (IM) on cancer-related fatigue in patients undergoing chemotherapy for early and advanced breast and gynecological (ovarian, endometrial, and cervical) cancer. METHODS: Patients reporting significant levels of fatigue (on the Edmonton Symptom Assessment Scale (ESAS), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), or Measure Yourself Concerns and Wellbeing questionnaire (MYCAW)) were offered complementary and integrative medicine (CIM) treatments in addition to standard supportive care...
June 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29878375/a-collaborative-surgical-approach-to-upper-and-lower-abdominal-cytoreductive-surgery-in-ovarian-cancer
#4
Oliver S Eng, Mustafa Raoof, Andrew M Blakely, Xian Yu, Stephen J Lee, Ernest S Han, Mark T Wakabayashi, Bertram Yuh, Byrne Lee, Thanh H Dellinger
BACKGROUND AND OBJECTIVES: Cytoreductive surgery with complete macroscopic resection in patients with ovarian cancer is associated with improved survival. Institutional reports of combined upper and lower abdominal cytoreductive surgery for more advanced disease have described multidisciplinary approaches. We sought to investigate outcomes in patients undergoing cytoreductive surgery in patients with upper and lower abdominal disease at our institution. METHODS: Patients who underwent cytoreductive surgery for ovarian malignancies from 2008 to 2015 were retrospectively identified from an institutional database...
June 7, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29876052/primary-bilateral-ovarian-burkitt-lymphoma-a-rare-issue-in-gynecologic-oncology
#5
Haneen Al-Maghrabi, Abdelrazak Meliti
We report a rare case of 42-year-old female patient with bilateral primary ovarian Burkitt lymphoma (BL). Primary BLs are rare ovarian oncology neoplasms. Only few cases are reported in English literature, most of them are presented in pediatric and young adult age groups. Rare cases are reported in adult females. Although BL is a rare primary ovarian neoplasm, it is very important to establish an accurate diagnosis as early as possible for therapeutic purposes.
May 2018: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/29873180/longitudinal-validation-and-comparison-of-the-chinese-version-of-the-european-organization-for-research-and-treatment-of-cancer-quality-of-life-chemotherapy-induced-peripheral-neuropathy-questionnaire-eortc-qlq-cipn20-and-the-functional-assessment-of-cancer
#6
Hui Lin Cheng, Alex Molassiotis
AIM: To validate and compare the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx) for measuring chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. METHODS: Patients were assessed with the EORTC QLQ-CIPN20, FACT/GOG-Ntx, National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) and World Health Organization criterion of CIPN (WHO-CIPN) from baseline up to 10 assessment points...
June 5, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29848738/an-instrument-for-estimating-the-6-month-survival-probability-after-whole-brain-irradiation-alone-for-cerebral-metastases-from-gynecological-cancer
#7
Stefan Janssen, Heinke C Hansen, Steven E Schild, Dirk Rades
BACKGROUND/AIM: Patients with cerebral metastases from gynecological cancer who receive whole-brain irradiation (WBI) alone require personalized therapy. This study contributes to personalized care by creating an instrument to predict 6-month survival probability. PATIENTS AND METHODS: In 49 patients, six pre-treatment variables, namely age, Eastern Cooperative Oncology Group performance score (ECOG-PS), primary tumor type, number of cerebral metastases, metastasis outside the brain, and interval between diagnosis of gynecological cancer and WBI, were analyzed for survival...
June 2018: Anticancer Research
https://www.readbyqxmd.com/read/29846243/gynecological-sarcomas-what-s-new-in-2018-a-brief-review-of-published-literature
#8
Justine Gantzer, Isabelle Ray-Coquard
PURPOSE OF REVIEW: In this article, we focus on recent published data (2017) on the management of gynecologic sarcomas. RECENT FINDINGS: The most significant data published in 2017 develop definition of a new molecular subtype of high grade endometrial stromal sarcoma (ESS) using molecular technics added to histological analysis. The identification of a new translocation on presumed uterine leiomyosarcoma (LMS) points to refinement of nosological classification, with fragmentation of even rare tumors into distinct molecular entities: gynecologic sarcomas are now distinguished into distinct entities from a heterogeneous group of tumors...
July 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29807695/postoperative-radiation-rates-in-stage-iia1-cervical-cancer-is-surgical-treatment-justified-an-israeli-gynecologic-oncology-group-study
#9
Yael Yagur, Omer Weitzner, Ofer Gemer, Ofer Lavie, Uziel Beller, Ilan Bruchim, Zvi Vaknin, Tally Levy, Alex Rabinovich, Inbar Ben Shachar, Amichay Meirovitz, Alon Ben Arie, Estela Derazne, Oded Raban, Ram Eitan, Yfat Kadan, Ami Fishman, Limor Helpman
OBJECTIVES: Data on the outcome of stage IIA1 cervical cancer is limited, as these tumors comprise a small percentage of early tumors. NCCN guidelines suggest consideration of surgical management for small tumors with vaginal involvement. Our objective was to evaluate the risk of adjuvant radiotherapy in stage IIA1 cervical cancer and its associated features, in order to improve selection of patients for surgical management. METHODS: A retrospective cohort study comparing surgically treated cervical cancer patients with stage IB1 and stage IIA1 disease...
May 25, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29807694/pre-operative-assessment-and-post-operative-outcomes-of-elderly-women-with-gynecologic-cancers-primary-analysis-of-nrg-cc-002-an-nrg-oncology-group-gynecologic-oncology-group-study
#10
Amina Ahmed, Wei Deng, William Tew, David Bender, Robert S Mannel, Ramey D Littell, Albert S DeNittis, Mitchell Edelson, Mark Morgan, Jay Carlson, Christopher J Darus, Aimee C Fleury, Susan Modesitt, Alexander Olawaiye, Anthony Evans, Gini F Fleming
INTRODUCTION: CC-002 is a prospective cooperative group study conducted by NRG Oncology to evaluate whether a pre-operative GA-GYN score derived from a predictive model utilizing components of an abbreviated geriatric assessment (GA) is associated with major post-operative complications in elderly women with suspected ovarian, fallopian tube, primary peritoneal or advanced stage papillary serous uterine (GYN) carcinoma undergoing primary open cytoreductive surgery. METHODS: Patients 70 years or older with suspected advanced gynecologic cancers undergoing evaluation for surgery were eligible...
May 25, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29804638/a-phase-ii-study-of-frontline-paclitaxel-carboplatin-bevacizumab-paclitaxel-carboplatin-temsirolimus-or-ixabepilone-carboplatin-bevacizumab-in-advanced-recurrent-endometrial-cancer
#11
Carol Aghajanian, Virginia Filiaci, Don S Dizon, Jay W Carlson, Matthew A Powell, Angeles Alvarez Secord, Krishnansu S Tewari, David P Bender, David M O'Malley, Ashley Stuckey, JianJiong Gao, Fanny Dao, Robert A Soslow, Heather A Lankes, Kathleen Moore, Douglas A Levine
OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating three novel agents into initial therapy. METHODS: In this randomized phase II trial, patients with chemotherapy-naïve stage III/IVA (with measurable disease) and stage IVB or recurrent (with or without measurable disease) endometrial cancer were randomly assigned to treatment with PC plus bevacizumab (Arm 1), PC plus temsirolimus (Arm 2) or ixabepilone and carboplatin (IC) plus bevacizumab (Arm 3)...
May 24, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29793429/predictive-equation-of-metastasis-in-patients-with-malignant-ovarian-epithelial-tumors-with-the-ca-125-marker
#12
Juan Fernando Sánchez Vega, Magdali Del Rocío Murillo Bacilio, Adrián Santiago Vintimilla Condoy, Araceli Miroslava Palta González, José Alfredo Crespo Astudillo, Franklin Geovany Mora-Bravo
BACKGROUND: Cancer antigen (CA) 125 (CA-125) is used in ovarian cancer detection and monitoring, whose serum level has a positive correlation with tumor stage. The aim of this study was to obtain a prediction metastasis equation in a group of patients with ovarian cancer based on Ca-125. METHODS: A 2-group comparative observational study was conducted at a single oncologic institution (SOLCA) in Cuenca-Ecuador. All patients who were diagnosed with ovarian cancer between January 1996 and December 2016 were included in the current study...
May 24, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29792852/is-there-a-survival-advantage-in-diagnosing-endometrial-cancer-in-asymptomatic-postmenopausal-patients-an-israeli-gynecology-oncology-group-study
#13
Ofer Gemer, Yakir Segev, Limor Helpman, Nasreen Hag-Yahia, Ram Eitan, Oded Raban, Zvi Vaknin, Sophia Leytes, Alon Ben Arie, Amnon Amit, Tally Levy, Ahmed Namazov, Michael Volodarsky, Inbar Ben Shachar, Ilan Atlas, Ilan Bruchim, Ofer Lavie
BACKGROUND: Incidental ultrasonographic findings in asymptomatic postmenopausal women, such as thickened endometrium or polyps, often lead to invasive procedures and to the occasional diagnosis of endometrial cancer. Data supporting a survival advantage of endometrial cancer diagnosed prior to the onset of postmenopausal bleeding (PMB) are lacking. OBJECTIVE: To compare the survival of endometrial cancer patients diagnosed in asymptomatic and bleeding post-menopausal patients...
May 21, 2018: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29778506/quality-of-life-symptoms-and-care-needs-in-patients-with-persistent-or-recurrent-platinum-resistant-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#14
Vivian E von Gruenigen, Helen Q Huang, David Cella, MichaelA Zevon, Jason A LaChance, Joan L Walker, Ritu Salani, Susan C Modesitt, Robert T Morris, William H Bradley, Matthew P Boente, Lari Wenzel
OBJECTIVES: The goals of treating recurrent platinum-resistant ovarian cancer are palliative, aimed at reducing symptoms and improving progression free survival. A prospective trial was conducted to determine the prevalence and severity of symptoms, and associated care needs. METHODS: Eligible women included those with persistent or recurrent platinum-resistant ovarian cancer with an estimated life expectancy of at least 6 months. The Needs at the End-of-Life Screening Tool (NEST), FACIT-Fatigue (FACIT-F), NCCN-FACT Ovarian Symptom Index [NFOSI-18]; Disease Related Symptoms (DRS), Treatment Side Effects (TSE), and Function/Well Being (F/WB) were collected at study entry, 3 and 6 months...
May 17, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29774521/patient-reported-outcomes-of-multiple-myeloma-patients-treated-with-panobinostat-after-%C3%A2-2-lines-of-therapy-based-on-the-international-phase-3-randomized-double-blind-placebo-controlled-panorama-1-trial
#15
Paul G Richardson, Robert L Schlossman, Anuja N Roy, Ashok Panneerselvam, Suddhasatta Acharyya, Monika Sopala, Sagar Lonial
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48...
May 17, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29770619/impact-of-lymph-node-ratio-on-survival-in-stage-iiic-endometrioid-endometrial-cancer-a-turkish-gynecologic-oncology-group-study
#16
Ali Ayhan, Nazlı Topfedaisi Ozkan, Murat Öz, Günsu Kimyon Comert, Zeliha Firat Cuylan, Gonca Çoban, Osman Turkmen, Baki Erdem, Hanifi Şahin, Özgür Akbayır, Murat Dede, Ahmet Taner Turan, Husnu Celik, Tayfun Güngör, Ali Haberal, Macit Arvas, Mehmet Mutlu Meydanli
OBJECTIVE: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). METHODS: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A total of 207 women were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (≤0...
March 13, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29762198/endometrial-cancer-in-the-elderly-does-age-influence-surgical-treatments-outcomes-and-prognosis
#17
Meriem Koual, Charlotte Ngo, Aude Girault, Fabrice Lécuru, Anne-Sophie Bats
OBJECTIVE: To compare clinicopathological characteristics, surgical outcomes, and survival rates for nonelderly (<75 years old) and elderly (≥75 years old) women with endometrial cancer (EC). METHODS: This retrospective study included consecutive patients who underwent surgery for EC at the gynecologic-oncologic surgery department of Hôpital Européen Georges-Pompidou (Paris, France) from January, 2002 to December, 2015. Independent-group t tests and chi-square tests were used to compare elderly and nonelderly women...
May 14, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29755762/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-ovarian-and-gastrointestinal-peritoneal-carcinomatosis-results-from-a-7-year-experience
#18
Giulia Montori, Federico Coccolini, Paola Fugazzola, Marco Ceresoli, Matteo Tomasoni, Carolina Rubicondo, Stefano Raimondo, Domenico Pinelli, Michele Colledan, Luigi Frigerio, Luca Ansaloni
Background: An increasing promising evidence and increasing long-term oncologic outcomes support the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as locoregional treatment for peritoneal carcinosis (PC) especially from ovarian and gastrointestinal tumors, but also for others cancers. Methods: A prospective monocentric study was performed in Papa Giovanni XXIII Hospital, Bergamo (Italy). Patients and tumor characteristics were analyzed...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29727351/comparison-of-different-surgical-approaches-for-stage-ib1-cervical-cancer-patients-a-multi-institution-study-and-a-review-of-the-literature
#19
Giacomo Corrado, Enrico Vizza, Francesco Legge, Luigi Pedone Anchora, Isabella Sperduti, Anna Fagotti, Emanuela Mancini, Valerio Gallotta, Ashanti Zampa, Benito Chiofalo, Giovanni Scambia
OBJECTIVE: The aim of this retrospective study was to assess the surgical and oncological outcome of 3 different surgical approaches (laparotomy, laparoscopy, and robotic surgery) in the treatment of early-stage cervical cancer International Federation of Gynecology and Obstetrics (FIGO) stage IB1. METHODS: All patients with a histologically confirmed diagnosis of early-stage cervical cancer, FIGO stage IB1, who underwent abdominal radical hysterectomy (ARH), laparoscopic radical hysterectomy, or robotic radical hysterectomy with or without pelvic and aortic lymphadenectomy were included in the study...
April 30, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29727349/the-feasibility-of-laparoscopic-surgery-in-gynecologic-oncology-for-obese-and-morbidly-obese-patients
#20
Jessie Peng, Sarah Sinasac, Katherine J Pulman, Liying Zhang, Joan Murphy, Tomer Feigenberg
BACKGROUND: Surgical interventions are the mainstay of treatment for many gynecological cancers. Although minimally invasive surgery offers many potential advantages, performing laparoscopic pelvic surgery in obese patients remains challenging. To overcome this, many centers have shifted their practice to robotic surgery; however, the high costs associated with robotic surgery are concerning and limit its use. OBJECTIVE: This study aimed to examine the feasibility of performing laparoscopic gynecologic oncology procedures in obese and morbidly obese patients...
June 2018: International Journal of Gynecological Cancer
keyword
keyword
59468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"